Cell Therapeutics, Inc. (cti) TRISENOX (arsenic trioxide) injection was approved today by the U.S. FDA to treat patients with a severe form of leukaemia whose disease has recurred or who have failed to respond to standard therapy. “For patients with APL whose disease has recurred following initial treatment, the use of salvage therapy is highly Read more about Cell Therapeutics Receives FDA Approval For Trisenox[…]